PT - JOURNAL ARTICLE AU - Maranhao, Andre AU - Bhadra, Sanchita AU - Paik, Inyup AU - Walker, David AU - Ellington, Andrew D. TI - An improved and readily available version of <em>Bst</em> DNA Polymerase for LAMP, and applications to COVID-19 diagnostics AID - 10.1101/2020.10.02.20203356 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.02.20203356 4099 - http://medrxiv.org/content/early/2020/10/05/2020.10.02.20203356.short 4100 - http://medrxiv.org/content/early/2020/10/05/2020.10.02.20203356.full AB - Despite the fact that strand-displacing activity is of great utility for a variety of applications, including isothermal amplification assays, there are relatively few strand-displacing DNA polymerases. In particular, the thermotolerant DNA polymerase from Geobacillus stearothermophilus (previously Bacillus stearothermophilus), Bst DNA polymerase (Bst DNAP), is used in a variety of assays, including loop-mediated isothermal amplification. However, despite its wide use, its properties remain open to improvement, as has been demonstrated by a variety of engineering efforts, including the identification of point mutations that impact its robustness, strand-displacement capabilities, and nascent reverse transcriptase activity.Interestingly, a strategy that has been commonly used to alter the capabilities of DNA polymerases, the addition of additional DNA- or RNA-binding domains, has yet to be applied to Bst DNAP. To this end, we now show that by adding fusion domains the performance of Bst DNAP in isothermal amplification assays, including its nascent RT activity, can be greatly improved. The impact of these improvements on the development of LAMP assays for the detection of SARS-CoV-2 is fully explored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health and the National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human subject studies were performed in this study. This study was performed under approval from the University of Texas at Austin IRB for the study number UT IRB # 2020-07-0011. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data pertaining to the study have been provided in the manuscript.